Vyvanse Should Be Avoided in Patients with Coronary Artery Disease
The FDA drug label explicitly states to "avoid VYVANSE use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease" due to reports of sudden death in such patients treated with CNS stimulants 1.
Why This Recommendation Exists
The FDA contraindication is based on serious safety concerns:
- Sudden death has been reported in patients with serious cardiac disease treated with CNS stimulants at recommended ADHD dosages 1
- Amphetamines increase cardiovascular stress through multiple mechanisms:
Supporting Evidence from Real-World Data
While the FDA label provides the definitive guidance, research data reinforces these concerns:
- Case reports document serious events: A 22-year-old man on lisdexamfetamine developed spontaneous coronary artery dissection 3, and a 32-year-old experienced branch retinal artery occlusion from vasospasm 4
- Long-term cardiovascular risks: A 2024 Swedish study found that longer cumulative ADHD medication use was associated with increased CVD risk, particularly hypertension (AOR 1.72-1.80 for >3 years use) and arterial disease 5
- Pharmacovigilance signals: Analysis of FDA adverse event reports identified significant safety signals for myocardial infarction, coronary artery dissection, and acute myocardial infarction with methylphenidate and amphetamines 6
Clinical Context
The one population-based study showing no increased MACE risk 7 compared lisdexamfetamine users to previous users of other ADHD medications—not to patients without stimulant exposure. This study does not address safety in patients with established CAD, and all participants were presumably screened to exclude serious cardiac disease per standard prescribing practices.
The Bottom Line
Do not prescribe Vyvanse to patients with known CAD. The FDA explicitly advises against this, prioritizing mortality risk over potential ADHD treatment benefits. If ADHD treatment is essential in a patient with CAD, consider non-stimulant alternatives like atomoxetine, guanfacine, or clonidine, which lack the sympathomimetic cardiovascular effects of amphetamines.
The risk-benefit calculation is clear: the potential for sudden death, myocardial infarction, coronary dissection, and sustained blood pressure/heart rate elevation in a patient with already-compromised coronary circulation outweighs ADHD symptom management benefits 1.